Literature DB >> 32343984

COVID-19: before stopping specific infection prevention and control measures, be sure to exclude the diagnosis.

E Farfour1, M-C Ballester2, M Lecuru3, A Verrat2, E Imhaus2, F Mellot4, F Karnycheff3, M Vasse3, C Cerf5, P Lesprit3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32343984      PMCID: PMC7194691          DOI: 10.1016/j.jhin.2020.04.021

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


× No keyword cloud information.
Sir, SARS-CoV-2 raises the challenge of controlling a pandemic within the community, and also preventing hospital transmission to medical staff and patients. As such, specific infection control measures are required. Following the recommendations of the French Health Authority, departments dedicated to patients with COVID-19 were implemented in our hospital. As the clinical presentation of COVID-19 is non-specific, a robust and accurate diagnosis is mandatory. According to the European Centre for Disease Control and Prevention, laboratory confirmation is required for suspected cases. Molecular testing of respiratory samples is considered to be the gold standard. Viral excretion appears early in the course of symptoms [1]. However, the turnaround times for the results of reverse transcriptase polymerase chain reaction (RT-PCR) often exceed 24 h, and laboratory diagnosis is threatened in some countries due to reagent shortages [2]. In contrast, cessation of scheduled medical activities means that computed tomography (CT) is readily available. Although chest CT might be non-specific, in the context of the pandemic, it has been proposed as an alternative to RT-PCR for early confirmation of COVID-19 [3]. We report six cases aged 62–80 years who had positive RT-PCR results. They all presented with symptoms compatible with viral pneumonia (fever >38.0°C with cough and/or dyspnoea) between 23rd and 27th March 2020. On admission, all were placed in isolation with suspected COVID-19 and nasopharyngeal swabs were obtained. Chest CT was performed rapidly in all patients and revealed no abnormalities. Four patients were discharged with a diagnosis of viral infection not due to SARS-CoV-2. The other two patients required hospital management; one patient stayed in the pre-admission zone until the RT-PCR result was available, and the other patient was transferred to a non-COVID department. Upon receipt of the RT-PCR-positive results, the discharged patients were contacted and given information about the disease, and the patient in the non-COVID department was transferred rapidly to a COVID department. These findings emphasize the need to: (i) apply standard precautions rigorously in all patients with respiratory symptoms; (ii) organize hospitals into specific departments for patients with COVID-19, patients without COVID-19 and a pre-admission zone for suspected cases awaiting diagnosis; (iii) delay transfer of patients with suspected COVID-19 until a final robust diagnosis has been made; and (iv) achieve faster turnaround times for the results of RT-PCR than currently available in many settings. Although RT-PCR is considered to be the gold standard for confirmation of a diagnosis of COVID-19, false-negative results have been reported [[3], [4], [5]]. Although chest CT is known to be negative for the first days after symptom onset, CT has been proposed for prompt diagnosis in the case of respiratory symptoms [3]. However, in these studies, RT-PCR was mainly performed on throat swabs, which probably display lower sensitivity [6]. Indeed, while the optimal sample has not been defined for SARS-CoV-2 RT-PCR, nasopharyngeal swabs are more sensitive for influenza viruses [7]. Furthermore, all of these studies included RT-PCR designed at the beginning of the pandemic when few viral genomes had been sequenced. Currently, according to the World Health Organization's recommendations, at least two viral targets should be amplified [8]. In the context of the pandemic, patients with COVID-19 should be admitted to specific wards. Suspected cases should be held in a pre-admission zone until a final robust diagnosis has been made. Our cases highlight significant difficulties associated with the diagnosis of COVID-19. Microbiological and radiological examinations are probably complementary, but both have limitations. The final diagnosis should be made by clinical assessment in conjunction with testing. Rapid and accurate molecular methods are needed urgently for this purpose.

Acknowledgements

The authors wish to thank all the teams at Foch Hospital involved in the care of patients with and without COVID-19. Members of the Sars-CoV-2 Foch Hospital study group: Emilie Catherinot, Colas Tcherakian, Louis-Jean Couderc, Clément Picard, Charlotte Roy, Sylvie Colin de Verdière and Antoine Roux (Service de pneumologie et transplantation pulmonaire); Benjamin Zuber, Richard Galliot, David Cortier and Mathilde Neuville (Service de réanimation); Morgan Le Guen (Service d’anesthésie); Mathilde Roumier, Antoine Bizard, David Zucman, David Khau and Romain Paule (Service de médecine interne); Emilie Jolly, Tiffany Pascreau, Laurence Mazaux, Marianne Asso-Bonnet, Gustavo Bazzouni-Barreiro, Floriane Grade, Sandrine Grandin, Marie de Fondaumière and Annabelle Marache (Service de Biologie Clinique); Philippe Grenier and Anne-Laure Brun (Service d’imagerie médicale); and Charlotte Rachline (Service des urgences).

Conflict of interest statement

None declared.

Funding sources

None.
  7 in total

1.  Detection of SARS-CoV-2 in Different Types of Clinical Specimens.

Authors:  Wenling Wang; Yanli Xu; Ruqin Gao; Roujian Lu; Kai Han; Guizhen Wu; Wenjie Tan
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

2.  Comparison of Respiratory Specimen Collection Methods for Detection of Influenza Virus Infection by Reverse Transcription-PCR: a Literature Review.

Authors:  Sarah Spencer; Mark G Thompson; Brendan Flannery; Alicia Fry
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

3.  Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.

Authors:  Tao Ai; Zhenlu Yang; Hongyan Hou; Chenao Zhan; Chong Chen; Wenzhi Lv; Qian Tao; Ziyong Sun; Liming Xia
Journal:  Radiology       Date:  2020-02-26       Impact factor: 11.105

4.  Viral load of SARS-CoV-2 in clinical samples.

Authors:  Yang Pan; Daitao Zhang; Peng Yang; Leo L M Poon; Quanyi Wang
Journal:  Lancet Infect Dis       Date:  2020-02-24       Impact factor: 25.071

5.  Experience of different upper respiratory tract sampling strategies for detection of COVID-19.

Authors:  G Ye; Y Li; M Lu; S Chen; Y Luo; S Wang; Y Wang; X Wang
Journal:  J Hosp Infect       Date:  2020-03-12       Impact factor: 3.926

6.  CT screening for early diagnosis of SARS-CoV-2 infection - Authors' reply.

Authors:  Heshui Shi; Xiaoyu Han; Yukun Cao; Osamah Alwalid; Chuansheng Zheng
Journal:  Lancet Infect Dis       Date:  2020-03-26       Impact factor: 25.071

7.  False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases.

Authors:  Dasheng Li; Dawei Wang; Jianping Dong; Nana Wang; He Huang; Haiwang Xu; Chen Xia
Journal:  Korean J Radiol       Date:  2020-03-05       Impact factor: 3.500

  7 in total
  4 in total

Review 1.  COVID-19 pandemic crisis-a complete outline of SARS-CoV-2.

Authors:  Sana Saffiruddin Shaikh; Anooja P Jose; Disha Anil Nerkar; Midhuna Vijaykumar Kv; Saquib Khaleel Shaikh
Journal:  Futur J Pharm Sci       Date:  2020-11-17

2.  SARS-CoV-2 RT-PCR and Chest CT, two complementary approaches for COVID-19 diagnosis.

Authors:  Eric Farfour; François Mellot; Philippe Lesprit; Marc Vasse
Journal:  Jpn J Radiol       Date:  2020-07-13       Impact factor: 2.374

3.  Evaluation of Four Fully Integrated Molecular Assays for the Detection of Respiratory Viruses during the Co-Circulation of SARS-CoV-2, Influenza and RSV.

Authors:  Eric Farfour; Thomas Yung; Robin Baudoin; Marc Vasse
Journal:  J Clin Med       Date:  2022-07-06       Impact factor: 4.964

4.  Carbapenemase-producing Enterobacterales outbreak: Another dark side of COVID-19.

Authors:  Eric Farfour; Marion Lecuru; Laurent Dortet; Morgan Le Guen; Charles Cerf; Françoise Karnycheff; Rémy A Bonnin; Marc Vasse; Philippe Lesprit
Journal:  Am J Infect Control       Date:  2020-10-02       Impact factor: 2.918

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.